Chief Financial Officer · HOOKIPA Pharma Inc. (HOOK)

Reinhard Kandera

A named executive officer of HOOKIPA Pharma in every fiscal year CompBrief holds from FY2022 to FY2023. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2023

$725,475

Salary $436,001Stock awards $0

FY2022: $715,161

3rd of 3 named executive officers at Hookipa Pharma by FY2023 total.

3 named officers on file for HOOKIPA Pharma, FY2023

Reinhard Kandera’s pay file — $29

  • 2 fiscal years of pay, line by line
  • 1 equity grant, each cited to its filing

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how HOOKIPA Pharma’s whole pay program stands against its peers

  • HOOKIPA Pharma’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on HOOK→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 26, 2024 (DEF 14A).

Free

Get Reinhard Kandera’s full pay file as a PDF — free

More than this page: up to 10 years of Reinhard’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

Reinhard Kandera compensation by year

HOOKIPA Pharma Summary Compensation Table · all 2 fiscal years held
In US dollars, as HOOKIPA Pharma reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2022FY2023
Salary$343,531$436,001
Bonus$0$0
Stock awards$0$0
Option awards$246,856$117,976
Non-equity incentive$112,678$156,960
Pension and deferred compensation$0$0
All other$12,096$14,538
Total$715,161$725,475

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: HOOKIPA Pharma Inc. DEF 14A filed April 26, 2024, accession 0001104659-24-052900, and prior-year filings. Open the filing on EDGAR.

How this page was built: the HOOKIPA Pharma Inc. filed document, accession 0001104659-24-052900. Every figure is read from that document and cited to the page and table it appears in. Filed April 26, 2024.

$715K
$725K
FY22
FY23
SalaryNon-equity incentiveOption awardsAll other

Equity holdings

unvested awards at FY2023 year-end
TypeUnvested unitsValue at year-endExercise price
Option214,800—$1.00
Option4,837—$8.03
Option21,656—$12.00
Option52,284—$1.66
Option52,284—$1.66

Per the Outstanding Equity Awards at Fiscal Year-End table in HOOKIPA Pharma Inc.'s FY2023 proxy; value at the fiscal year-end close, as the company printed it.

HOOKIPA Pharma’s named executive officers, FY2023

as the company reported each
Named executive officerRoleFY2023 total
Joern AldagChief Executive Officer$1,130,427
Christine BakerFormer Chief Operating Officer$813,399
Reinhard Kandera · this pageChief Financial Officer$725,475

The full HOOKIPA Pharma compensation record

free company brief

This page is one person within HOOKIPA Pharma's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are HOOKIPA Pharma's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Reinhard Kandera's compensation dossier · One-time report. No refunds.